A Phase 1 interventional study of MK-8527 in Healthy and HIV Pre-exposure Prophylaxis, sponsored by Merck Sharp & Dohme LLC. Completed at 2 sites in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-16.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this study is to learn how MK-8527 moves through the healthy person's body over time. Researchers will measure for the amount of MK-8527 in breast milk that the baby will receive at many time points.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The key inclusion criteria include but are not limited to the following:
Exclusion Criteria:
The key exclusion criteria include but are not limited to the following
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive single oral dose of MK-8527 on Day 1
Drug: MK-8527
Oral administration
Area Under the Concentration-Time Curve from Time 0 to 120 hours (AUC0-120hrs) After Administration of a Single Oral Dose of MK-8527 in Breast Milk
Breast milk samples will be collected to determine the AUC0-120hrs after administration of a single oral dose of MK-8527.
Time frame: Predose and at designated timepoints up to 120 hours postdose
Maximum Breast Milk Concentration (Cmax) After Administration of a Single Oral Dose of MK-8527
Breast milk samples will be collected to determine the Cmax after administration of a single oral dose of MK-8527.
Time frame: Predose and at designated timepoints up to 21 days postdose
Time to Maximum Breast Milk Concentration (Tmax) After Administration of a Single Oral Dose of MK-8527
Breast milk samples will be collected to determine the Tmax after administration of a single oral dose of MK-8527.
Time frame: Predose and at designated timepoints up to 21 days postdose
Mean Concentration of MK-8527 in Breast Milk After Administration of a Single Oral Dose
Breast milk samples will be collected to determine the mean concentration of MK-8527.
Time frame: Predose and at designated timepoints up to 120 hours postdose
Amount Excreted in Breast Milk From Time Zero to 120 Hours (Ae0-120hrs) After Administration of a Single Oral Dose of MK-8527
Breast milk samples will be collected to determine the Ae0-120hrs after administration of a single oral dose of MK-8527.
Time frame: Predose and at designated timepoints up to 120 hours postdose
Area Under the Concentration-Time Curve from Time 0 to 120 hours (AUC0-120hrs) After Administration of a Single Oral Dose of MK-8527 in Blood
Blood samples will be collected to determine AUC0-120hrs after administration of a single oral dose of MK-8527.
Time frame: Predose and at designated timepoints up to 120 hours postdose
Area Under the Concentration-Time Curve from Time 0 to Time-Infinity (AUC0-Inf) After Administration of a Single Oral Dose of MK-8527 in Blood
Blood samples will be collected to determine AUC0-inf after administration of a single oral dose of MK-8527.
Time frame: Predose and at designated timepoints up to 21 days postdose
Maximum Blood Concentration (Cmax) After Administration of a Single Oral Dose of MK-8527
Blood samples will be collected to determine the Cmax after administration of a single oral dose of MK-8527.
Time frame: Predose and at designated timepoints up to 21 days postdose
Time to Maximum Blood Concentration (Tmax) After Administration of a Single Oral Dose of MK-8527
Blood samples will be collected to determine the Tmax after administration of a single oral dose of MK-8527.
Time frame: Predose and at designated timepoints up to 21 days postdose
Area Under the Concentration-Time Curve from Time 0 to 120hours (AUC0-120hrs) After Administration of a Single Oral Dose of MK-8527 in Plasma
Plasma samples will be collected to determine AUC0-120hrs after administration of a single oral dose of MK-8527.
Time frame: Predose and at designated timepoints up to 120 hours postdose
Area Under the Concentration-Time Curve from Time 0 to Time-Infinity (AUC0-Inf) After Administration of a Single Oral Dose of MK-8527 in Plasma
Plasma samples will be collected to determine AUC0-inf.
Time frame: Predose and at designated timepoints up to 7 days postdose
Maximum Plasma Concentration (Cmax) After Administration of a Single Oral Dose of MK-8527
Plasma samples will be collected to determine the Cmax after administration of a single oral dose of MK-8527.
Time frame: Predose and at designated timepoints up to 7 days postdose
Time to Maximum Plasma Concentration (Tmax) After Administration of a Single Oral Dose of MK-8527
Plasma samples will be collected to determine the Tmax after administration of a single oral dose of MK-8527.
Time frame: Predose and at designated timepoints up to 7 days postdose
Ratio of MK-8527 in Breast Milk to Blood After Administration of a Single Dose of MK-8527
Ratio of MK-8527 in breast milk to blood will be used to estimate dose of MK-8527.
Time frame: At designated timepoints up to 120 hours postdose
Ratio of MK-8527 in Breast Milk to Plasma After Administration of a Single Oral Dose
Ratio of MK-8527 in breast milk to plasma will be used to estimate dose of MK-8527.
Time frame: At designated timepoints up to 120 hours postdose
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Apr 2025 to primary completion in Mar 2026, 11 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alimatravir